Targeted radiation drug shows promise for tough brain tumors

NCT ID NCT07655869

Recruiting now Disease control Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new radioactive drug, [177Lu]Lu-DOTA-EB-RGD2, in 24 patients with recurrent high-grade glioma, a fast-growing brain cancer. The drug is designed to seek out and deliver radiation directly to tumor blood vessels. It can be given through a vein or directly into the brain tumor cavity via a small device under the scalp. The main goals are to check safety, find the best dose, and see if the drug can slow tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A radioactive drug that targets tumor blood vessels, given by IV or directly into the brain tumor cavity
What this could lead to: If it works, this could point toward a new treatment option for recurrent high-grade glioma, a brain cancer with few effective therapies.
What could go wrong: This is a very early Phase 1 trial with only 24 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or improve survival, and there are risks of serious side effects like brain swelling or seizures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IDH-wildtype glioblastoma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA, IDH-WILDTYPE RECURRENT HIGH-GRADE GLIOMAS

Contacts and locations

Locations

Beijing Tiantan Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100070, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITING

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.